Edition:
United Kingdom

Ludwig Burger

GSK's long acting HIV injection gets boost from study

22 Aug 2019

GlaxoSmithKline's experimental HIV injection is as effective when given every other month as monthly, according to a study, a convenience that could help the British drugmaker in its battle against a rival drug from Gilead Sciences.GSK's two-drug injection was as effective as a monthly dose of the same regimen in maintaining viral suppression at 48 weeks in a late-stage study, said ViiV Healthcare, GSK's HIV unit.

Elanco to become No.2 in animal health with $7.6 billion Bayer deal

20 Aug 2019

Elanco Animal Health agreed to buy Bayer's veterinary drugs unit on Tuesday in a cash and stock deal valued at $7.6 billion (£6.3 billion), creating the second largest maker of medicines for pets and livestock and expanding Elanco's reach online.

AstraZeneca diabetes drug shows promise in heart failure

20 Aug 2019

AstraZeneca made strides on Tuesday towards its goal of adding heart failure to the conditions that can be treated by its diabetes drug Farxiga, putting it ahead of a rival medicine from Eli Lilly .

Shares of Germany's SGL tumble after profit warning, CEO resignation

15 Aug 2019

FRANKFURT Shares of German carbon fibre maker SGL Group tumbled 32% to their lowest in nearly 17 years on Thursday after the company withdrew its forecasts for the next three years and said its CEO quit over flawed business planning.

Bayer mediator dismisses report of $8 billion Roundup settlement

10 Aug 2019

NEW YORK/FRANKFURT Bayer AG has not offered to pay billions of dollars to settle claims in the United States related to the Roundup herbicide, mediator Ken Feinberg said, dismissing a report to that effect which drove its shares as much as 11% higher.

Bayer buys BlueRock in $600 million bet on stem cell therapies

08 Aug 2019

FRANKFURT German drugmaker Bayer is paying up to $600 million for full control of cell therapy developer BlueRock Therapeutics, stepping up investment in a promising new medical area to revive its drug development pipeline.

Merck KGaA's profit bolstered by lab supplies, drug milestone payments

08 Aug 2019

FRANKFURT Germany's Merck KGaA posted a gain in quarterly earnings that was slightly higher than market expectations thanks to strong sales growth at its lab supplies unit and milestone payments from drug development partners.

Lanxess, Bayer sell chemical park operator to Macquarie for $3.9 billion

07 Aug 2019

FRANKFURT German chemical groups Bayer and Lanxess have agreed to sell integrated chemical site operator Currenta to Macquarie Infrastructure and Real Assets (MIRA) for an enterprise value of 3.5 billion euros ($3.9 billion).

World News